StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) shareholders

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
97.4%
14M of 15M shares
Institutional holders
163
52 new, 21 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
20 buys · 5 sales
Net bought $6.07M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Perceptive Advisors LLC
Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
1,489,4439.99%13G (passive) amendmentJun 30, 2026
Viking Global Opportunities Parent GP LLC
Joint filing with Viking Global Investors LP (9.99%), Halvorsen Ole Andreas (9.99%) and 4 more
1,461,6339.99%13G (passive) amendmentMar 31, 2026
Joseph Edelman
Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
1,461,1059.99%13G (passive) amendmentMar 31, 2026
Viking Global Investors LP
Joint filing with Viking Global Opportunities Parent GP LLC (9.30%), Halvorsen Ole Andreas (9.30%) and 4 more
1,383,6219.30%13G (passive) amendmentJun 30, 2026
Sanofi1,157,9268.00%13G (passive)May 30, 2024
Morgan Stanley
Joint filing with Morgan Stanley Capital Services LLC (6.30%)
1,155,4167.90%13G (passive)Dec 31, 2025
Jon Faiz Kayyem1,149,0467.90%13D (active) amendmentJun 3, 2024
Mark Lappe925,4136.40%13D (active) amendmentSep 12, 2024
Schonfeld Strategic Advisors LLC781,6785.33%13G (passive)Jun 30, 2026
BlackRock, Inc.768,1305.30%13G (passive)Dec 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of INBXValueChange% of portfolio
Morgan Stanley1,308,0518.89%$123.94M+44,9730.01%
Perceptive Advisors LLC1,297,7638.82%$122.96M−144,9441.85%
Sanofi1,157,9267.87%$109.71M–20.54%
Viking Global Investors LP1,123,9297.64%$106.49M−313,7760.30%
HighTower Advisors, LLC870,5515.92%$82.48M+3510.08%
Bank Of America Corp /De/841,1415.72%$79.70M+808,4580.01%
BlackRock, Inc.825,9725.61%$78.26M+27,0740.00%
Schonfeld Strategic Advisors LLC697,5864.74%$66.10M+442,7590.24%
State Street Corp640,4584.35%$60.68M+89,6130.00%
Vanguard Capital Management LLC492,4773.35%$46.66M+6,0550.00%
Woodline Partners LP400,8922.72%$37.98M+16,4590.12%
Capital Research Global Investors363,0502.47%$34.40M−29,7970.00%
Goldman Sachs Group Inc338,1762.30%$32.04M+243,1020.00%
PFM Health Sciences, LP308,3852.10%$29.22M+2,9542.51%
Sofinnova Investments, Inc.303,1032.06%$28.72M−102,9261.48%
Healthcare Of Ontario Pension Plan Trust Fund271,7001.85%$25.74M+101,0000.04%
Parkman Healthcare Partners LLC256,9501.75%$24.35MNew2.49%
Geode Capital Management, LLC256,1751.74%$24.28M+24,6660.00%
First Turn Management, LLC164,7831.12%$15.61MNew1.67%
Millennium Management LLC147,2001.00%$13.95M−180,6600.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202616314M97.4%52 / 5639 / 213M2M
Q1 202613513M86.4%25 / 5336 / 272M1M
Q4 202513813M87.0%45 / 3838 / 83M1M
Q3 202510211M71.4%25 / 2334 / 112M2M
Q2 20258810M70.9%10 / 2234 / 141M1M
Q1 20259211M73.3%9 / 1837 / 161M1M
Q4 202410211M76.1%17 / 3130 / 103M1M
Q3 2024969M60.7%22 / 3518 / 112M2M
Q2 20248710M66.0%87 / 00 / 010M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

149 funds held INBX in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of INBXValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF1,645,97311.18%$1.07M0.01%Jun 30, 2026
iShares Russell 2000 ETF794,4365.40%$1.33M0.00%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF401,0272.72%$38.00M0.35%Jun 30, 2026
Vanguard Total Stock Market Index Fund369,6412.51%$35.02M0.00%Jun 30, 2026
SMALLCAP World Fund Inc353,2922.40%$33.47M0.04%Jun 30, 2026
iShares Russell 2000 ETF244,1181.66%$23.13M0.03%Jun 30, 2026
The Merger Fund198,5091.35%$223.32K0.01%Jun 30, 2026
iShares Russell 2000 Growth ETF193,2981.31%$322.81K0.00%Jun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares164,1731.12%$00.00%Jul 31, 2026
Vanguard Extended Market Index Fund109,8830.75%$10.41M0.01%Jun 30, 2026
iShares Russell 2000 Value ETF106,1850.72%$177.33K0.00%Jun 30, 2026
Fidelity Small Cap Index Fund103,9380.71%$8.53M0.03%Jul 31, 2026
Meridian Small Cap Growth Fund96,9150.66%$69.78K0.03%Jun 30, 2026
Tax-Managed U.S. Mid & Small Cap Fund95,1500.65%$61.61K0.00%Jul 31, 2026
iShares Biotechnology ETF76,6250.52%$7.26M0.08%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mark LappeChief Executive Officer, Director970,4536.59%Oct 14, 2026
David MatlyPresident––Apr 27, 2026
Kelly DeckChief Financial Officer––Apr 2, 2025
Jon Faiz KayyemDirector1,074,0467.30%Sep 23, 2026
Douglas ForsythDirector227,0641.54%Sep 18, 2026
Kristiina Vuori MDDirector20,4430.14%Sep 18, 2026
Kimberly ManhardDirector7,5000.05%Sep 18, 2026
David C. Ott10% owner––Oct 9, 2025
Global Opportunities GP LLC Viking10% owner––Oct 9, 2025
Global Opportunities Illiquid Investments Sub-Master LP Viking10% owner––Oct 9, 2025
Global Opportunities Portfolio GP LLC Viking10% owner––Oct 9, 2025
Rose Sharon Shabet10% owner––Oct 9, 2025
Global Opportunities Parent GP LLC Viking10% owner102,8640.70%Oct 9, 2025
Ole Andreas Halvorsen10% owner83,3330.57%Oct 9, 2025
Global Investors Lp Viking10% owner––Oct 9, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Mark Lappe
Chief Executive Officer, Director
Oct 14, 2026Buy+100$85.76$8.58K170,000
Mark Lappe
Chief Executive Officer, Director
Oct 14, 2026Buy+2,451$85.00$208.33K169,900
Mark Lappe
Chief Executive Officer, Director
Oct 14, 2026Buy+2,449$84.07$205.89K167,449
Mark Lappe
Chief Executive Officer, Director
Oct 14, 2026Buy+100$85.76$8.58K745,588
Mark Lappe
Chief Executive Officer, Director
Oct 14, 2026Buy+2,470$85.00$209.95K745,488
Mark Lappe
Chief Executive Officer, Director
Oct 14, 2026Buy+2,470$84.07$207.65K743,018
Mark Lappe
Chief Executive Officer, Director
Sep 28, 2026Buy+3,000$101.70$305.10K740,548
Mark Lappe
Chief Executive Officer, Director
Sep 28, 2026Buy+1,500$98.88$148.32K737,548
Mark Lappe
Chief Executive Officer, Director
Sep 25, 2026Buy+2,176$99.60$216.73K736,048
Mark Lappe
Chief Executive Officer, Director
Sep 25, 2026Buy+3,324$98.87$328.64K733,872
Jon Faiz Kayyem
Director
Sep 23, 2026Buy+5,000$100.00$500.00K434,360
Jon Faiz Kayyem
Director
Sep 16, 2026Buy+5,000$100.00$500.00K429,360
Kimberly Manhard
Director
Sep 15, 2026Sale−500$105.05$52.53K7,500
Kimberly Manhard
Director
Sep 14, 2026Sale−500$110.26$55.13K8,000
Kimberly Manhard
Director
Sep 11, 2026Sale−500$111.78$55.89K8,500
Kimberly Manhard
Director
Sep 9, 2026Sale−500$115.80$57.90K9,000
Kimberly Manhard
Director
Sep 8, 2026Sale−500$115.14$57.57K9,500
Douglas Forsyth
Director
Sep 8, 2026Buy+2,500$114.65$286.63K227,064
Mark Lappe
Chief Executive Officer, Director
Sep 8, 2026Buy+1,100$107.12$117.83K719,148
Mark Lappe
Chief Executive Officer, Director
Sep 8, 2026Buy+6,605$100.64$664.73K718,048
Mark Lappe
Chief Executive Officer, Director
Sep 8, 2026Buy+5,895$99.29$585.31K711,443
Mark Lappe
Chief Executive Officer, Director
Sep 8, 2026Buy+1,219$111.88$136.38K720,867
Mark Lappe
Chief Executive Officer, Director
Sep 8, 2026Buy+9,681$112.28$1.09M730,548
Mark Lappe
Chief Executive Officer, Director
Sep 8, 2026Buy+500$108.24$54.12K719,648
Jon Faiz Kayyem
Director
Sep 8, 2026Buy+5,000$113.52$567.60K424,360
Global Opportunities Parent GP LLC Viking
10% owner
Oct 7, 2025Sale−25,042$32.25$807.60K102,864
Global Opportunities Parent GP LLC Viking
10% owner
Oct 7, 2025Sale−308,643$32.25$9.95M1,267,823
Global Opportunities Parent GP LLC Viking
10% owner
Oct 7, 2025Sale−16,315$32.25$526.16K67,018
Jon Faiz Kayyem
Director
Mar 27, 2025Gift−90,000––419,360
Jon Faiz Kayyem
Director
Dec 16, 2024Gift+250,000––250,000
Jon Faiz Kayyem
Director
Dec 16, 2024Gift−500,000––509,360
Jon Faiz Kayyem
Director
Dec 16, 2024Gift+250,000––250,000
Jon Faiz Kayyem
Director
Dec 6, 2024Gift−52,000––1,009,360
Jon Faiz Kayyem
Director
Nov 20, 2024Buy+18,750$14.19$266.06K69,843
Jon Faiz Kayyem
Director
Nov 20, 2024Buy+18,750$14.19$266.06K69,843
Jon Faiz Kayyem
Director
Nov 19, 2024Buy+34,843$14.23$495.82K51,093
Jon Faiz Kayyem
Director
Nov 19, 2024Buy+34,843$14.23$495.82K51,093
Kristiina Vuori MD
Director
Oct 3, 2024Buy+6,667$15.00$100.01K20,443
Mark Lappe
Chief Executive Officer, Director
Sep 16, 2024Buy+13,037$17.13$223.32K705,548
Mark Lappe
Chief Executive Officer, Director
Sep 12, 2024Buy+26,963$15.05$405.79K692,511
Kristiina Vuori MD
Director
Sep 11, 2024Buy+6,457$15.07$97.31K13,776
Kristiina Vuori MD
Director
Sep 10, 2024Buy+179$15.00$2.69K7,319
Mark Lappe
Chief Executive Officer, Director
Sep 10, 2024Buy+8,500$15.19$129.12K665,548
Mark Lappe
Chief Executive Officer, Director
Sep 9, 2024Buy+9,500$15.21$144.50K657,048
Mark Lappe
Chief Executive Officer, Director
Sep 6, 2024Buy+26,000$15.29$397.54K647,548
Mark Lappe
Chief Executive Officer, Director
Sep 3, 2024Buy+15,288$15.66$239.41K160,288
Mark Lappe
Chief Executive Officer, Director
Sep 3, 2024Buy+4,712$16.31$76.85K165,000
Mark Lappe
Chief Executive Officer, Director
Aug 30, 2024Buy+10,000$14.02$140.20K145,000
Kristiina Vuori MD
Director
Aug 29, 2024Buy+7,140$14.00$99.96K7,140
Mark Lappe
Chief Executive Officer, Director
Aug 29, 2024Buy+10,000$14.03$140.30K135,000
Kimberly Manhard
Director
Aug 28, 2024Buy+10,000$13.98$139.80K10,000
Douglas Forsyth
Director
Aug 23, 2024Buy+59,812$14.07$841.55K224,564
Douglas Forsyth
Director
Aug 22, 2024Buy+15,188$12.89$195.77K164,752
Mark Lappe
Chief Executive Officer, Director
Aug 21, 2024Buy+12,945$12.93$167.38K54,865
Mark Lappe
Chief Executive Officer, Director
Aug 20, 2024Buy+27,055$12.97$350.90K41,920
Jon Faiz Kayyem
Director
Jun 24, 2024Gift+10,000––16,250
Jon Faiz Kayyem
Director
Jun 24, 2024Gift−89,050––1,061,360
Jon Faiz Kayyem
Director
Jun 24, 2024Gift+10,000––16,250
Jon Faiz Kayyem
Director
Jun 5, 2024Buy+49,284$17.23$849.16K1,142,145
Jon Faiz Kayyem
Director
Jun 5, 2024Buy+8,265$17.89$147.86K1,150,410

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
35.66%
3M shares short
Days to cover
10.0
At 0M shares a day
Change since last report
-0.8%
From 3M shares
Short volume, 20 days
66.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inhibrx Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 31,034 shares on Sep 15, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Kimberly Manhard
Director
Sep 15, 2026500$52.53KSep 15, 2026Open Market Purchase
Kimberly Manhard
Director
Sep 14, 2026500$55.13KSep 14, 2026Open Market Purchase
Kimberly Manhard
Director
Sep 11, 2026500$55.89KSep 11, 2026Open Market Purchase
Kimberly Manhard
Director
Sep 9, 2026500$57.90KSep 9, 2026Open Market Purchase
Kimberly Manhard
Director
Sep 8, 2026500$57.57KSep 8, 2026Open Market Purchase

See a number that looks wrong?